Phase II trial of induction gefitinib followed by cisplatin and docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer with EGFR activating mutation.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 20 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Feb 2011 New trial record